Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine, towards integrated management strategies

  • García-Castillo, María Clara
  • Sierra Mencia, Álvaro|||0000-0002-0022-6064
  • Caronna, Edoardo|||0000-0001-5525-0267
  • Toledo-Alfocea, Daniel|||0000-0003-3651-1614
  • Jaimes, Alex|||0000-0002-0890-9484
  • Urtiaga, Saray
  • Casas-Limón, Javier|||0000-0002-7353-4084
  • Muñoz-Vendrell, Albert|||0000-0001-8221-865X
  • Santos Lasaosa, Sonia|||0000-0002-4141-7705
  • García Martín, Valvanuz
  • Martín Ávila, Guillermo
  • Polanco Fernández, Marcos
  • Villar-Martínez, Maria Dolores|||0000-0003-3920-0176
  • Trevino-Peinado, Cristina|||0000-0001-8711-4884
  • Rubio-Flores, Laura|||0000-0001-5570-8055
  • Sánchez-Soblechero, Antonio|||0000-0002-7098-8494
  • Portocarrero Sánchez, Leonardo
  • Luque-Buzo, Elisa|||0000-0002-7983-9268
  • Lozano Ros, Alberto|||0000-0002-5186-8657
  • Gago-Veiga, Ana Beatriz|||0000-0002-0038-3406
  • Díaz de Terán, Javier|||0000-0003-0064-6269
  • Recio García, Andrea
  • Canales Rodríguez, Javiera
  • Gómez García, Andrea
  • González Salaices, Marta
  • Campoy Diaz, Sergio|||0000-0002-8135-4139
  • Mínguez-Olaondo, Ane|||0000-0002-7742-3920
  • Maniataki, Stefania
  • González-Quintanilla, Vicente|||0000-0003-0902-3906
  • Porta-Etessam, Jesús|||0000-0002-7034-682X
  • Cuadrado, María Luz|||0000-0001-8246-3743
  • Guerrero Peral, Ángel Luis|||0000-0001-7493-6002
  • Pozo-Rosich, Patricia|||0000-0003-0796-4702
  • Rodríguez-Vico, Jaime|||0000-0001-9360-5444
  • Huerta, Mariano|||0000-0003-0181-5335
  • Pascual Gómez, Julio|||0000-0002-3189-7573
  • Goadsby, Peter J.|||0000-0003-3260-5904
  • Gonzalez-Martinez, Alicia|||0000-0002-1228-1503
Preclinical evidence supports the immunoregulatory role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. The increasing use of anti-CGRP therapies in patients with migraine and other comorbidities raises the question whether the potential use of anti-CGRP monoclonal antibodies (CGRP-mAbs) therapies in combination with other immunological therapies is effective and safe. This multicenter study included patients with migraine receiving CGRP-mAbs combined with immunosuppressive and immunomodulatory treatments. Clinical and demographic data, treatment history, laboratory markers and treatment-emergent adverse events (TEAEs) were analyzed. Effectiveness outcomes included the change in monthly migraine days (MMD) and monthly headache days (MHD) at 3, 6, 9 and 12 months, alongside the.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Prediction of Left Ventricular Thrombus After Myocardial Infarction: A Cardiac Magnetic Resonance-Based Prospective Registry

  • Bertolín-Boronat, Carlos
  • Marcos-Garcés, Víctor
  • Merenciano-Gonzalez, Héctor
  • Perez, Nerea
  • Pérez del Villar, Candelas
  • Lopez-Lereu, Maria P.
  • Monmeneu, Jose V.
  • Herrera Flores, Cristian
  • Domenech-Ximenos, Blanca
  • Lopez Fornas, F
  • Rios-Navarro, César
  • De Dios, Elena
  • Ortiz-Perez, Jose T.
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] Background: Left ventricular thrombus (LVTh) is a severe complication after ST-segment elevation myocardial infarction (STEMI). Objectives: We aim to predict LVTh occurrence by cardiac magnetic resonance (CMR) using clinical, echocardiographic, and electrocardiographic (ECG) variables readily available at admission. Methods: We included 590 reperfused STEMI patients who underwent early (1-week) and/or late (6-month) CMR in our institution. Baseline clinical, echocardiographic (left ventricular ejection fraction -LVEF-) and ECG data (summatory of ST-segment elevation -sum-STE- and Q-wave and residual ST-elevation >1 mm -Q-STE-) during admission were registered. Multivariate binary logistic regression models and receiver operating characteristic curves were computed for LVTh prediction. Results: LVTh was detected by CMR in 43 (7.3 %) patients and was predicted by previous chronic coronary syndrome (CCS, HR 4.74 [1.82-12.35], p = 0.001), anterior STEMI (HR 10.93 [2.47-48.31], p = 0.002), LVEF (HR 0.96 [0.93-0.99] per %, p = 0.008), maximum sum-STE (HR 1.04 [1.01-1.07] per mm, p = 0.04), and Q-STE (HR 1.31 [1.08-1.6] per lead, p = 0.008). High-risk patients with both major (anterior STEMI and Q-STE in >= 1 leads) and 1-3 minor (CCS, maximum sum-STE >10 mm, LVEF <50%) factors showed the highest LVTh risk (19.6 % within 6 months). The model showed excellent discrimination ability (area under the curve=0.85 [0.81-0.9], p < 0.001). Simplified 4-variable (excluding sum-STE) and 3-variable (also excluding CCS) risk scores showed similar discrimination ability and were externally validated. Conclusions: LVTh within 6 months post-STEMI can be predicted using pre-discharge clinical (anterior infarction and CCS), echocardiographic (LVEF), and ECG (sum-STE and Q-STE) data. Our results can help select patients who should undergo CMR after STEMI for LVTh detection., This work was supported by Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI20/00637, PI23/01150, CIBERCV16/11/00486, CIBERCV16/11/00420, CIBERCV16/11/00479, CIBERCV16/11/00292 and postgraduate contracts CM21/00175, CM23/00246 and CM23/00238) and by Conselleria de Innovacion, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (PROMETEO/2021/008).Dr. Marcos-Garces acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant JR23/00032), as well as a GE 2023 grant from the Conselleria de Innovacion, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (CIGE/2022/26).Dr. Gavara has received financial support from the Agencia Estatal de Investigacion (grant FJC2020-043981-I/AEI/10.13039/501100011033).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Depression, Anxiety, and Quality of Life in a Cardiac Rehabilitation Program Without Dedicated Mental Health Resources Post-Myocardial Infarction

  • C Bertolin-Boronat
  • Marcos-Garcés, Víctor
  • Merenciano-Gonzalez H
  • Martínez Mas, Maria Luz
  • Climent Alberola, Josefa Inés
  • Pérez, Nerea
  • Lopez Bueno, Laura
  • Esteban Argente, Maria Concepcion
  • Valls Reig, Maria
  • Arizon Benito, Ana
  • Paya Rubio, Alfonso
  • Rios-Navarro, César
  • De Dios, Elena
  • Gavara, Jose
  • Jiménez-Navarro, Manuel F.
[EN] Anxiety and depression are common after a myocardial infarction (MI), so psychological and psychiatric mental health (MH) interventions are recommended during Cardiac Rehabilitation Programs (CRP). We aim to evaluate anxiety and depression symptoms and quality of life in MI sufferers followed in a CRP without dedicated MH resources. We prospectively included 164 MI patients in our CRP without dedicated MH resources. Patient Health Questionnaire 2-item (PHQ-2) and Generalized Anxiety Disorder 2-item (GAD-2) questionnaires for depression and anxiety screening (altered if >= 3 points) and the 36-Item Short Form Survey Instrument (SF-36) to analyze four MH components and Mental Component Summary (MCS) were assessed at the beginning and after CRP. The mean age was 61.35 +/- 10.76 years, and most patients were male (86.6%). A significant improvement in SF-36 mental components (from +5.94 +/- 27.98 to +8.31 +/- 25 points, p < 0.001) and SF-36-MCS (+1.85 +/- 10.23 points, p = 0.02) was noted, as well as a reduction in depression and anxiety symptoms in PHQ-2 and GAD-2 (p < 0.001). However, 33 (20.1%) patients showed a positive screening for depression and/or anxiety at the end of the program. These patients were younger (56.6 +/- 8.05 vs. 62.55 +/- 11.05 years, p = 0.004) and showed significantly worse initial scores of SF-36 mental components, PHQ-2, and GAD-2 (p < 0.001). We conclude that a Phase 2 CRP without dedicated MH resources can achieve significant improvements in MH well-being after MI. However, one-fifth of the population had substantial depression and/or anxiety symptoms at the end of the program. This subset, characterized by worse initial MH scores, may benefit from specific MH interventions during CRP., This research was funded by Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI20/00637, PI23/01150, CIBERCV16/11/00486, CIBERCV16/11/00420, CIBERCV16/11/00479 and postgraduate contracts CM21/00175 and CM23/00246) and by Conselleria de Educacion of the Generalitat Valenciana (PROMETEO/2021/008). Dr. Marcos-Garces acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant JR23/00032). Drs. Rios-Navarro and Gavara acknowledge funding from the Conselleria de Educacion-Generalitat Valenciana and co-funding from Fondo Social Europeo Plus (grant numbers CIAPOS/2023/247, and CIAPOS2023/248).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Left ventricular remodeling after myocardial infarction pathophysiology, diagnostic approach and management during Cardiac Rehabilitation

  • Marcos-Garcés, Víctor
  • Bertolín-Boronat, Carlos
  • Merenciano-Gonzalez, Héctor
  • Martínez Mas, Maria Luz
  • Climent Alberola, Josefa Inés
  • Lopez Bueno, Laura
  • Paya Rubio, Alfonso
  • Pérez-Solé, Nerea
  • Rios-Navarro, César
  • De Dios, Elena
  • Rodríguez-Palomares, Jose F.
  • Ortiz-Perez, Jose T.
  • Sanchis, Juan
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] Despite the improvement in prognosis in patients with acute myocardial infarction (AMI), a significant proportion of survivors still experience heart failure (HF)-related adverse outcomes. Adverse left ventricular remodeling (LVR), which refers to a progressive dilation of left ventricular (LV) end-diastolic and end-systolic volumes, usually accompanied by a deterioration in LV systolic function, occurs frequently and underlies most cases of HF development after AMI. In this review, we discuss the current definitions of post-AMI LVR, the most appropriate imaging modalities for its detection, and the pathophysiological mechanisms by which Cardiac Rehabilitation (CR) can improve LVR-including exercise interventions, cardiovascular risk factors control, and pharmacological therapy optimization. Finally, we provide up-to-date recommendations for the follow-up and management of LVR in post-AMI patients enrolled in CR and outline future prospects on this topic., This research was funded by the Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI23/01150, PI15/00531, CB16/11/00486, CB16/11/00420, and CB16/11/00479 and postgraduate contracts CM21/00175 and CM23/00246) and by Conselleria de Educacion of the Generalitat Valenciana (CIPROM/2024/028). Dr. Marcos-Garces acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant JR23/00032), as well as a GE 2023 grant from the Conselleria de Innovacion, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (CIGE/2022/26). Dr. Ortiz-Perez acknowledges partial financial support from Fundacio La Marato de TV3 (grant number 20153030-31-32), Siemens Healthcare, and La Caixa Banking Foundation (HR17-00527). Dr. Gavara acknowledges funding from the Conselleria de Educacion-Generalitat Valenciana and co-funding from Fondo Social Europeo Plus (grant number CIAPOS/2023/247). Dr. Moratal has received financial support from the Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana (grants AEST/2019/037 and AEST/2020/029).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Dynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program

  • Bertolin-Boronat, C
  • Merenciano-Gonzalez H
  • Marcos-Garcés, Víctor
  • Martínez-Mas, Maria Luz
  • Climent Alberola, Josefa Ines
  • Pérez, Nerea
  • López-Bueno, Laura
  • Esteban-Argente, Maria Concepcion
  • Reig, Maria
  • Arizon Benito, Ana
  • Paya Rubio, Alfonso
  • Rios-Navarro, César
  • De Dios, Elena
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
[EN] Background: Exercise-based cardiac rehabilitation programs (CRP) are recommended for patients following acute coronary syndrome to potentially improve high-density lipoprotein cholesterol (HDL-C) levels and prognosis. However, not all patients reach target HDL-C levels. Here we analyze the dynamics and predictors of HDL-C increase during CRP in patients following ST-segment elevation myocardial infarction or occlusion myocardial infarction. Methods: We conducted a prospective study of myocardial infarction patients who completed exercise-based Phase 2 CRP. Data was collected on clinical variables, cardiovascular risk factors, treatment goals, pharmacological therapy, and health outcomes through questionnaires at the beginning and at the end of Phase 2 CRP. Lipid profile analysis was performed before discharge, 4 to 6 weeks after discharge, and at the end of Phase 2 CRP. Changes in lipid profiles were evaluated, and predictors of failure to increase HDL-C levels were identified by binary logistic regression analysis. Results: Our cohort comprised 121 patients (mean age 61.67 +/- 10.97 years, 86.8% male, and 47.9% smokers before admission). A significant decrease in total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) were noted, along with an increase in HDL-C (43.87 +/- 9.18 vs. 39.8 +/- 10.03 mg/dL, p < 0.001). Patients achieving normal HDL-C levels (>40 mg/dL in men and >50 mg/dL in women) significantly increased from 34.7% at admission to 52.9% the end of Phase 2. Multivariable analysis revealed smoking history (hazard ratio [HR] = 0.35, 95% confidence interval [CI], 0.11-0.96, p = 0.04), increased reduction in total cholesterol (HR = 0.94, 95% CI, 0.89-0.98, p = 0.004), and increased reduction in LDL-C (HR = 0.94, 95% CI, 0.89-0.99, p = 0.01) were inversely associated with failure to increase HDL-C levels. Conversely, higher HDL-C before CRP (HR = 1.15, 95% CI, 1.07-1.23, p < 0.001) and increased lipoprotein (a) (HR = 1.01, 95% CI, 1-1.02, p = 0.04) predicted failure to increase HDL-C levels. No significant correlations were found with Mediterranean diet adherence, weekly physical activity, training modalities, or physical fitness parameters. Conclusions: Participation in an exercise-based Phase 2 CRP led to mild but significant increases in HDL-C. Smoking history and patients experiencing substantial reductions in total cholesterol and LDL-C were more likely to experience HDL-C increases, unlike those with higher HDL-C and lipoprotein (a) levels before CRP., This research was funded by Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI20/00637, PI23/01150, CIBERCV16/11/00486, CIBERCV16/11/00420, CIBERCV16/11/00479 and postgraduate contracts CM21/00175 and CM23/00246) and by Conselleria de Educación of the Generalitat Valenciana (PROMETEO/2021/008). Dr. Marcos-Garcés acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant number JR23/00032), as well as a GE 2023 grant from the Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (CIGE/2022/26). Drs. Ríos-Navarro and Gavara acknowledge funding from the Conselleria de Educación Generalitat Valenciana and co-funding from Fondo Social Europeo Plus (grant numbers CIAPOS/2023/247 and CIAPOS2023/248)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Familial Hypercholesterolemia Screening in a Cardiac Rehabilitation Program After Myocardial Infarction

  • Bertolin-Boronat, Carlos
  • Marcos-Garcés, Víctor
  • Merenciano-Gonzalez, Héctor
  • Martínez Mas, Maria Luz
  • Climent Alberola, Josefa Inés
  • Pérez, Nerea
  • Lopez Bueno, Laura
  • Esteban Argente, Maria Concepcion
  • Valls Reig, Maria
  • Arizon Benito, Ana
  • Paya Rubio, Alfonso
  • Rios-Navarro, César
  • De Dios, Elena
  • Jiménez-Navarro, Manuel F.
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
[EN] Familial hypercholesterolemia (FH) is relatively prevalent in myocardial infarction (MI) sufferers, and its diagnosis could improve preventive treatment in family members. We aim to analyze the diagnosis of FH and the rate of genetic testing in a prospective cohort of 245 patients submitted to our Cardiac Rehabilitation Program (CRP) after MI. Baseline characteristics were registered, and basal low-density lipoprotein cholesterol (LDL-C) was calculated after correction for lipid-lowering therapies (LLT) before or during admission. Simplified Dutch Lipid Clinic Network Scores (sDLCNS) were retrospectively calculated based on personal and familial history of premature cardiovascular disease and basal LDL-C levels. Mean age was 62.19 +/- 13.93 years, and most patients were male (81.6%). Mean LDL-C before admission and basal LDL-C corrected for LLT were 131.79 +/- 45.34 mg/dL and 162.87 +/- 44.17 mg/dL, respectively. Patients in the cohort were retrospectively categorized in the "unlikely" (<3 points; n = 162, 66.1%), "possible" (3-5 points; n = 72, 29.4%) and "probable" (6-8 points; n = 11, 4.5%) sDLCNS categories. Genetic testing for FH was requested in four (1.6%) patients, and no clinically significant genetic variants were detected. Patients who underwent genetic testing depicted significantly higher basal LDL-C (233 +/- 49.09 vs. 161.71 +/- 43.25 mg/dL, p = 0.001). However, the rate of individuals undergoing genetic testing was negligible even in the "possible" (n = 2, 2.8%) and "probable" (n = 1, 9.1%) sDLCNS categories. In conclusion, genetic testing for FH in our CRP after MI is largely underutilized, even in patients with a "possible" or "probable" diagnosis based on sDLCNS criteria, which represent about a third of the cohort. Strategies to improve screening for FH should be prospectively implemented., This work was supported by grants from "Instituto de Salud Carlos III", "Fondos Europeos de Desarrollo Regional FEDER" and "Fondo Social Europeo Plus (FSE+)" (grant numbers PI20/00637, PI23/01150, and CIBERCV16/11/00486, a postgraduate contract FI18/00320 to C.R.-N., CM23/00246 to H.M.-G., and CM21/00175 and JR23/00032 to V.M.-G.) and Conselleria de Educacion-Generalitat Valenciana (PROMETEO/2021/008). C.R.-N. and J.G. acknowledge funding from the Conselleria de Educacion-Generalitat Valenciana and co-funding from Fondo Social Europeo Plus (grant numbers CIAPOS/2023/247, and CIAPOS2023/248).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Short-Course High-Intensity Statin Treatment during Admission for Myocardial Infarction and LDL-Cholesterol Reduction-Impact on Tailored Lipid-Lowering Therapy at Discharge

  • Marcos-Garces, Victor
  • Merenciano-Gonzalez, Héctor
  • Martinez Mas, Maria Luz
  • Palau, Patricia
  • Climent Alberola, Josefa Ines
  • Pérez, Nerea
  • Lopez-Bueno, Laura
  • Esteban Argente, Maria Concepcion
  • Valls Reig, Maria
  • Muñoz Alcover, Raquel
  • Pradillas Contreras, Inmaculada
  • Arizon Benito, Ana
  • Paya Rubio, Alfonso
  • Rios-Navarro, César
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
[EN] We hypothesized that a short-course high-intensity statin treatment during admission for myocardial infarction (MI) could rapidly reduce LDL-C and thus impact the choice of lipid-lowering therapy (LLT) at discharge. Our cohort comprised 133 MI patients (62.71 +/- 11.3 years, 82% male) treated with atorvastatin 80 mg o.d. during admission. Basal LDL-C levels before admission were analyzed. We compared lipid profile variables before and during admission, and LLT at discharge was registered. Achieved theoretical LDL-C levels were estimated using LDL-C during admission and basal LDL-C as references and compared to LDL-C on first blood sample 4-6 weeks after discharge. A significant reduction in cholesterol from basal levels was noted during admission, including total cholesterol, triglycerides, HDL-C, non-HDL-C, and LDL-C (-39.23 +/- 34.89 mg/dL, p < 0.001). LDL-C levels were reduced by 30% in days 1-2 and 40-45% in subsequent days (R-2 0.766, p < 0.001). Using LDL-C during admission as a reference, most patients (88.7%) would theoretically achieve an LDL-C < 55 mg/dL with discharge LLT. However, if basal LDL-C levels were considered as a reference, only a small proportion of patients (30.1%) would achieve this lipid target, aligned with the proportion of patients with LDL-C < 55 mg/dL 4-6 weeks after discharge (36.8%). We conclude that statin treatment during admission for MI can induce a significant reduction in LDL-C and LLT at discharge is usually prescribed using LDL-C during admission as the reference, which leads to insufficient LDL-C reduction after discharge. Basal LDL-C before admission should be considered as the reference value for tailored LLT prescription., This work was supported by grants from Instituto de Salud Carlos III , Fondos Europeos de Desarrollo Regional FEDER , and Fondo Social Europeo Plus (FSE + ) (grant numbers PI20/00637, PI23/01150, and CIBERCV16/11/00486, and CM21/00175 and JR23/00032 to V.M.-G.), Conselleria de Educación Generalitat Valenciana (PROMETEO/2021/008) and GE 2023 grant by the Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (CIGE/2022/26). J.G. acknowledges financial support from the Agencia Estatal de Investigación (grant FJC2020-043981-I).
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publication Artículo científico (JournalArticle)

El poder del comedor escolar como herramienta de salud: sinergias entre la política pública y el programa E-DUCASS, The impact of the school lunchroom as a health tool: Synergies between public policy and the E-DUCASS program

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Editorial: Insights in gastroenterology: 2022

  • Lanas, Ángel
  • Hijos-Mallada, Gonzalo
Gastrointestinal endoscopy is one of these areas undergoing major developments, with several emerging endoscopic techniques in recent years. Submucosal tunnel endoscopic resection (STER) is an advanced procedure, developed for the resection of gastrointestinal submucosal tumors (SMTs). STER offers the advantages of maintaining mucosal integrity, given that it is less invasive than surgery (1, 2). However, scarce evidence is available regarding risk factors associated with technical complexity and complications. To shed light on this topic, Lv et al. performed a retrospective analysis of the outcomes of 66 SMTs located in the upper gastrointestinal tract managed by STER. The median size of the SMTs was 18 mm, and most (80%) were originated in the muscularis propria. Complete resection and en bloc resection were achieved in 66 (100%) and 64 (97%) patients, with a median procedure time of 45 min. STER-related complications were observed in 10 (15%) of the patients, all managed by conservative treatment. Multivariable analysis revealed that tumor size was an independent risk factor for prolonged procedure time (>60 min), complications, and long hospital stay (>6 days). A tumor size of ≥25 mm was identified as the optimal threshold to define high-risk patients. In such cases, STER should be performed by a more experienced team, or other treatments should be considered..
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies

  • García-Castillo, María Clara
  • Sierra-Mencía, Álvaro
  • Caronna, Edoardo
  • Toledo-Alfocea, Daniel
  • Jaimes, Alex
  • Urtiaga, Saray
  • Casas-Limón, Javier
  • Muñoz-Vendrell, Albert
  • Santos Lasaosa, Sonia
  • García Martín, Valvanuz
  • Martín Ávila, Guillermo
  • Polanco, Marcos
  • Villar-Martínez, Maria Dolores
  • Trevino-Peinado, Cristina
  • Rubio-Flores, Laura
  • Sánchez-Soblechero, Antonio
  • Portocarrero Sánchez, Leonardo
  • Luque-Buzo, Elisa
  • Lozano-Ros, Alberto
  • Gago-Veiga, Ana Beatriz
  • Díaz-De-Terán, Javier
  • Recio García, Andrea
  • Canales Rodríguez, Javiera
  • Gómez García, Andrea
  • González Salaices, Marta
  • Campoy, Sergio
  • Mínguez-Olaondo, Ane
  • Maniataki, Stefania
  • González-Quintanilla, Vicente
  • Porta-Etessam, Jesús
  • Cuadrado, María-Luz
  • Guerrero Peral, Ángel Luis
  • Pozo-Rosich, Patricia
  • Rodríguez-Vico, Jaime
  • Huerta-Villanueva, Mariano
  • Pascual, Julio
  • Goadsby, Peter J.
  • Gonzalez-Martinez, Alicia
Preclinical evidence supports the immunoregulatory role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. The increasing use of anti-CGRP therapies in patients with migraine and other comorbidities raises the question whether the potential use of anti-CGRP monoclonal antibodies (CGRP-mAbs) therapies in combination with other immunological therapies is effective and safe. Methods. This multicenter study included patients with migraine receiving CGRP-mAbs combined with immunosuppressive and immunomodulatory treatments. Clinical and demographic data, treatment history, laboratory markers and treatment-emergent adverse events (TEAEs) were analyzed. Effectiveness outcomes included the change in monthly migraine days (MMD) and monthly headache days (MHD) at 3, 6, 9 and 12 months, alongside the > 50% response rate. Moreover, autoimmune disease progression was also evaluated. We explored differences between patients with and without autoimmune disease activation. Results.Among 89 patients, there were 80 (90%) females with a mean age of 50 years (SD: 11), who had a high prevalence of psychiatric comorbidities (anxiety 44%, depression 49%) and medication overuse (68%). Patients receiving immunological treatments experienced significant reductions in MMD and MHD, with MMD decreasing from 16 (SD: 7) at baseline to 9 (SD: 8) at 6 months, and MHD dropping from 23 (SD: 8) to 17 (SD: 11). A 50% response in MMD was achieved by 46% at 6 months. TEAEs were reported in 28%, most commonly constipation (16%) and dizziness (9%). Conclusions. CGRP-mAbs therapies combined with immunological treatments appear effective and safe in patients with autoimmune diseases. Larger prospective studies are necessary to confirm these findings and optimize management strategies.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Angiogenic factors and fetal Doppler for predicting adverse pregnancy outcome in early-onset small fetuses with and without pre-eclampsia

  • Casellas de Miguel, Alba
  • Dalmau Artal, Marta
  • Díaz Fernández, Patricia
  • Temprado Piqueras, Joaquin
  • Duaso, M.
  • Ampurdanés Noró, Queralt
  • Armengol, T.
  • Lizarraga, Z.
  • Bonacina, Erika
  • Armengol Alsina, Mireia
  • Roldán Alarcón, Eva
  • San José Moya, Marta
  • Maiz, Nerea
  • Mendoza, Manel
Doppler; Angiogenic factors; Fetal growth restriction, Doppler; Factores angiogénicos; Restricción del crecimiento fetal, Doppler; Factors angiogènics; Restricció del creixement fetal, Objectives To assess the predictive performance of angiogenic factors and fetal Doppler, alone and in combination, for composite adverse perinatal outcome (CAPO) in early-onset small-for-gestational age (SGA) and fetal growth restriction (FGR), in cases both with and without pre-eclampsia (PE), in order to evaluate the ability of these markers to predict adverse outcomes beyond their established association with PE and to better delineate the specific contribution of PE to their predictive value. Methods This was a retrospective observational study conducted at Vall d'Hebron University Hospital, Barcelona, Spain, between January 2016 and January 2022. The study population included singleton pregnancies with an estimated fetal weight < 10th percentile, diagnosed with fetal smallness between 20 + 0 and 31 + 6 weeks' gestation, with fetal Doppler ultrasound data and available angiogenic factor measurements obtained at diagnosis. Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) were measured at initial assessment. CAPO was defined as the presence of at least one of the following: 5-min Apgar score < 7; umbilical cord arterial pH < 7.0; admission to the neonatal intensive care unit for > 48 h; stillbirth; neonatal death; respiratory distress syndrome; bronchopulmonary dysplasia; neonatal sepsis; necrotizing enterocolitis; Grade-III–IV retinopathy of prematurity; Grade-III–IV intraventricular hemorrhage; or periventricular leukomalacia. Predictive performance for CAPO and subsequent PE was assessed using receiver-operating-characteristics (ROC)-curve analysis and area under the ROC curve (AUC) comparisons for fetal Doppler and angiogenic factors, alone and combined, within logistic regression models. Sensitivity, false-positive rate, positive predictive value and negative predictive value were calculated. All analyses were stratified according to PE development at any time before delivery. Results Overall, 469 women with an early-onset small fetus were included. PE was present at diagnosis in 74/469 (15.8%) cases and developed later in 83 (17.7%) cases. CAPO occurred in 46.5% of cases. In the overall cohort, PlGF combined with fetal Doppler findings showed the highest predictive performance for CAPO (AUC, 0.866 (95% CI, 0.833–0.899)), outperforming fetal Doppler alone. Notably, the performance of the combined model was not significantly different from PlGF alone (AUC, 0.862 (95% CI, 0.828–0.895); P = 0.621). These findings were consistent in pregnancies without PE, in which PlGF remained the best-performing single predictor of CAPO (AUC, 0.797 (95% CI, 0.740–0.854)). In pregnancies with PE at any time, the best-performing single predictor was the sFlt-1/PlGF ratio (AUC, 0.802 (95% CI, 0.728–0.876)). For the prediction of subsequent PE after enrolment, the sFlt-1/PlGF ratio alone (AUC, 0.861 (95% CI, 0.821–0.901)) and in combination with fetal Doppler (AUC, 0.862 (95% CI, 0.822–0.902)) achieved the highest predictive performance. Combining fetal Doppler findings with angiogenic factors reduced false-positive rates, but did not improve sensitivity. Conclusion This study confirmed the robust predictive performance of PlGF and the sFlt-1/PlGF ratio for identifying CAPO and PE in early-onset SGA/FGR. The predictive value of PlGF and fetal Doppler remained consistent irrespective of PE status, while the sFlt-1/PlGF ratio showed reduced predictive accuracy in non-PE pregnancies, but still outperformed Doppler. These findings support the integration of angiogenic factors into the clinical assessment of early-onset SGA/FGR, for both cases with and those without PE. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., E.B. has been funded by Instituto de Salud Carlos III (ISCIII) through the project ‘JR23/00004’ and cofunded by the European Union. M.A.-A. has been funded by ISCIII through the project ‘CM23/00017’ and cofunded by the European Union. M.M. and E.B. received lecture fees from Roche Diagnostics.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Optimizing Chronic Migraine Care: The Impact of Advanced Practice Nurse Involvement in OnabotulinumtoxinA Administration

  • Gine-Cipres, Eulalia
  • Gallardo López, Víctor J.
  • TORRES-FERRUS, MARTA
  • Alpuente Ruiz, Alicia
  • Caronna, Edoardo
  • Gómez Dabó, Laura
  • Pozo-Rosich, Patricia
Advanced practice nursing; Botulinum toxin type A; Headache, Infermeria de pràctica avançada; Toxina botulínica tipus A; Mal de cap, Enfermería de práctica avanzada; Toxina botulínica tipo A; Dolor de cabeza, Background: Chronic migraine is a disabling and prevalent neurological disease that significantly impacts patients' quality of life. OnabotulinumtoxinA (OnabotA) is a safe and effective chronic migraine preventive treatment. The objective was to evaluate adherence to the recommended time interval between consecutive OnabotA injections according to the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) protocol, and to analyze changes in the interval adherence before and after the introduction of an Advanced Practice Nurse (APN) in a specialized Headache Unit of a tertiary hospital. Methods: This was a retrospective study performed in a Spanish specialized Headache Clinic. Patients diagnosed with chronic migraine and treated with OnabotA following the PREEMPT protocol were included, before and after the introduction of APNs. Treatment was considered interval-compliant if the injection interval ranged from 75 to 105 days. The data collected included three 18-month periods. Statistical analyses examined differences across periods using R-Studio. Results: A total of 2991 participants were included, of whom 83.8% (2507/2991) were women, with a median age [interquartile range (IQR)] of 48.0 [40.0–57.0] years old. A statistically significant association between the introduction of the APN and improved adherence to the PREEMPT protocol was observed over time (Z = –19.60, p < 0.001). Adherence rates increased from 52.1% in P1 to 76.1% in both P2 and P3. The median time between visits decreased from 105 days in P1 to 96 days in P2, with a slight increase to 98 days in P3. Conclusion: The involvement of advanced practice nurses in OnabotA administration decreased the time interval between infiltrations and improved adherence to the PREEMPT protocol. These findings highlight the APN's role in optimizing patient care.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cost–benefit analysis of first-trimester pre-eclampsia screening: comparison of multivariable Gaussian algorithm with and without placental growth factor, Análisis de costo-beneficio de la detección de la preeclampsia en el primer trimestre: comparación del algoritmo multivariable de Gauss con y sin factor de crecimiento placentario

  • Armengol Alsina, Mireia
  • Dalmau Artal, Marta
  • Casellas de Miguel, Alba
  • Roldán Alarcón, Eva
  • Kumari , Neeti
  • Arias García, Andrea
  • Bonacina, Erika
  • del Barco Martínez, Ester
  • Ferrer Costa, Roser
  • Maiz, Nerea
  • Mendoza, Manel
First trimester; Pre‐eclampsia; Screening, Primer trimestre; Preeclampsia; Cribado, Primer trimestre; Preeclàmpsia; Cribratge, Objective Pre-eclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Early identification of high-risk pregnancies in the first trimester allows preventive treatment with low-dose aspirin. This study aimed to evaluate whether multivariable Gaussian algorithm-based PE screening strategies, with and without placental growth factor (PlGF), are cost beneficial compared with no screening. Methods The cost–benefit analysis estimated the total healthcare savings for the two screening strategies compared with no screening, considering both the costs associated with implementing the screening and the savings derived from the number of cases of PE and preterm infants prevented. The analysis was based on real-world data from Catalan maternity centers applied to a cohort of 56 344 pregnancies (annual birth rate in 2023). Univariable sensitivity and best- and worst-case scenario analyses were also conducted. Results Both screening strategies resulted in cost savings compared with no screening. The Gaussian algorithm without PlGF yielded greater healthcare savings (€3.38 million) than did the Gaussian algorithm with PlGF (€3.29 million). However, the addition of PlGF provided greater clinical benefit, preventing a higher number of PE cases. Sensitivity analysis identified PE incidence and preterm birth rates as the primary cost drivers. For the PlGF strategy to be cost beneficial, the PlGF reagent cost per unit should not exceed €4.31. Conclusions Although the Gaussian algorithm without PlGF demonstrated the highest cost savings compared with no screening, incorporating PlGF further improved PE prevention, supporting its broader adoption. A PlGF reagent cost per unit below €4.31 may make this strategy cost-beneficial, enhancing its clinical implementation. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., Objetivo La preeclampsia (PE) es una de las principales causas de morbilidad y mortalidad materna y neonatal en todo el mundo. La identificación precoz de los embarazos de alto riesgo en el primer trimestre permite el tratamiento preventivo con dosis bajas de aspirina. El objetivo de este estudio fue evaluar si las estrategias de detección de la PE basadas en algoritmos multivariables de Gauss, con y sin factor de crecimiento placentario (FCPl), son rentables en comparación con la ausencia de pruebas de detección. Métodos El análisis de costo-beneficio estimó el ahorro sanitario total de las dos estrategias de detección en comparación con la ausencia de pruebas de detección, para lo cuál se consideraron tanto los costos asociados a las pruebas de detección como el ahorro derivado de la prevención del número de casos de PE y de recién nacidos prematuros. El análisis se basó en datos reales de centros de maternidad catalanes aplicados a una cohorte de 56 344 embarazos (tasa de natalidad anual en 2023). También se realizaron análisis de sensibilidad univariable y análisis de escenarios de mejor y peor caso. Resultados Ambas estrategias de detección supusieron un ahorro de costos en comparación con la ausencia de pruebas de detección. El algoritmo de Gauss sin FCPl produjo un mayor ahorro sanitario (3,38 millones de euros) que el algoritmo de Gauss con FCPl (3,29 millones de euros). Sin embargo, la adición del FCPl proporcionó un mayor beneficio clínico, ya que evitó un mayor número de casos de PE. El análisis de sensibilidad identificó la frecuencia de PE y las tasas de nacimientos prematuros como los principales generadores de costos. Para que la estrategia con FCPl sea rentable, el costo por unidad del reactivo FCPl no debe superar los 4,31 euros. Conclusiones Aunque el algoritmo de Gauss sin FCPl demostró un mayor ahorro de costos en comparación con la ausencia de pruebas de detección, la incorporación del FCPl mejoró aún más la prevención de la PE, lo que apoya su adopción más amplia. Un coste unitario del reactivo FCPl inferior a 4,31 euros puede hacer que esta estrategia sea rentable, lo que favorecería su aplicación clínica., We thank all physicians and participants who agreed to take part in the original studies, and Roche Diagnostics for providing the reagents. We also thank Ciro Salvi for preparing the figures for this paper. E.B. was funded by Instituto de Salud Carlos III (ISCIII) through the project “JR23/00004” and co-funded by the European Union. M.A-A. was funded by Instituto de Salud Carlos III (ISCIII) through the project “CM23/00017” and co-funded by the European Union. M.M. and E.B. received lecture fees from Roche Diagnostics.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Neck pain in migraine: A narrative review and steps to correct evaluation and treatment

  • Rees, Tayla
  • Doukhi, Diana
  • Wang, Victor S
  • Balcerbula, Anita
  • Bravo, Michelle
  • fathi, haniyeh
  • Caronna, Edoardo
  • Pozo-Rosich, Patricia
Evaluation; Migraine; Neck pain, Avaluació; Migranya; Dolor cervical, Evaluación; Migraña; Dolor cervical, Background Neck pain is common in migraine patients, occurring during all migraine phases and between attacks. It can be a migraine symptom, trigger or a coexisting condition, and is associated with greater disability and poorer treatment response. There is evidence that neck pain associated with headaches can be frequently incorrectly diagnosed as a cervical disorder rather than migraine, resulting in a lack of appropriate treatment. Accurately assessing the connection between neck pain and migraine is crucial for effective treatment. Methods This narrative review aims to summarise existing research on the role and contribution of neck pain in migraine, both as a symptom and a trigger, and outlines future research needed to deepen our understanding of this relationship. It also proposes a structured approach for assessing neck pain in migraine and a treatment algorithm, offering guidance for clinical evaluation and treatment. For this purpose, a comprehensive narrative review was conducted using PubMed, covering preclinical, clinical, neurophysiological and imaging evidence on migraine and neck pain. Results Migraine patients frequently exhibit cervical dysfunction, tenderness and altered posture, with overlapping neuroanatomical pathways of the neck and trigeminal systems, suggesting shared mechanisms of nociception and migraine initiation. Clinical assessment involves a thorough history, physical exam and exclusion of secondary causes. Standard migraine therapies, such as amitriptyline and onabotulinumtoxinA, may help reduce neck pain and non-pharmacological treatments, such as physical therapy, acupuncture and behavioural strategies, show some promise. However, evidence on neck pain relief is limited. Conclusions Accurately distinguishing whether neck pain is a symptom, trigger or comorbid condition in migraine is essential for guiding effective treatment strategies. Both pharmacological and non-pharmacological approaches may help manage migraine-associated neck pain. However, few studies have assessed the effects of acute or preventive migraine therapies, particularly calcitonin gene-related peptide-targeted treatments, on neck pain, highlighting a significant gap in our current knowledge. Future research should evaluate the effectiveness of these therapies on neck pain, both alone and in combination with non-pharmacological interventions., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: TAR acknowledges receipt of the International Headache Society Fellowship from the International Headache Society. EC’s salary has been partially funded by Río Hortega grant Acción Estratégica en Salud 2017–2020 from Instituto de Salud Carlos III (CM20/00217) and Juan Rodés fellowship, Subprograma Estatal de Incorporación de la Acción Estratégica en Salud 2023 (JR23/00065).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Early treatment in migraine – A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society

  • Özge, Aynur
  • Pozo-Rosich, Patricia
  • Caronna, Edoardo
  • Sacco, Simona
  • Peres, Mario F P
  • Ashina, Sait
Anti-CGRP therapies; Migraine preventive treatment; Preventive treatment, Terapias anti-CGRP; Tratamiento preventivo de la migraña; Tratamiento preventivo, Teràpies anti-CGRP; Tractament preventiu de la migranya; Tractament preventiu, Migraine is one of the most disabling diseases worldwide, especially when it transforms into chronic migraine, which is often associated with medication overuse and can become resistant or even refractory to treatments. Molecular, neuroimaging and neurophysiological changes have been described in chronic migraine, some of which might not be fully reversible with preventive treatment. For these reasons, we should aim to prevent this transition, and initiate preventive treatment before disease becomes refractory and burden increases. Preventive migraine treatments are often delayed because of access to care, stigma leading to undertreatment and patients' reluctance as a result of fear of side effects and, in some cases, fear of being labeled as chronically ill. With the availability of effective and well-tolerated preventive treatments, we must shift our mindset and take advantage of new opportunities to initiate preventive treatment earlier. In this International Headache Society position statement, we propose a migraine preventive strategy under the idea of shifting from reactive treatment once disability is established (prevention of attacks), to proactive, individualized prevention initiated early with safe, effective and tolerable therapies (prevention of disease progression). This approach is based on 1) promoting the early initiation of effective and tolerable preventive therapies, starting from two to four monthly migraine days in line with the majority of current guidelines and recommendations and 2) fostering longitudinal studies to gather more evidence on the potential benefit of early prevention, with the final goal of improving patient outcomes, promoting excellent migraine care, enhancing individual and social well-being, and, ultimately, preventing migraine progression and preserving brain health., EC has received honoraria from Novartis, Chiesi, Lundbeck, MedScape, Lilly, TEVA, Organon and Dr Reddy's; his salary has been partially funded by Río Hortega grant Acción Estratégica en Salud 2017–2020 from Instituto de Salud Carlos III (CM20/00217) and Juan Rodés fellowship, Subprograma Estatal de Incorporación de la Acción Estratégica en Salud 2023 (JR23/00065). He is a junior editor for Cephalalgia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

RE-START, Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine

  • Romero del Rincón, Celia|||0000-0002-0339-6616
  • Gonzalez-Martinez, Alicia|||0000-0002-1228-1503
  • Quintas, Sonia|||0000-0003-0622-8228
  • Garcia Azorin, David|||0000-0002-3132-1064
  • Fernández-Lázaro, Iris|||0009-0004-2544-5206
  • Guerrero Peral, Ángel Luis|||0000-0001-7493-6002
  • González Osorio, Yésica|||0000-0003-1461-9798
  • Santos Lasaosa, Sonia|||0000-0002-4141-7705
  • González Oria, Carmen
  • Sánchez Rodríguez, Norberto
  • Iglesias Díez, Fernando
  • Echavarría Íñiguez, Ana|||0000-0001-7038-2911
  • Gil Luque, Sendoa
  • Huerta, Mariano|||0000-0003-0181-5335
  • Campoy Diaz, Sergio|||0000-0002-8135-4139
  • Muñoz-Vendrell, Albert|||0000-0001-8221-865X
  • Lozano Ros, Alberto|||0000-0002-5186-8657
  • Sánchez-Soblechero, Antonio|||0000-0002-7098-8494
  • Velasco Juanes, Fernando
  • Kortazar-Zubizarreta, Izaro|||0000-0002-8107-660X
  • Echeverría, Amaya|||0000-0001-9225-5323
  • Rodríguez-Vico, Jaime|||0000-0001-9360-5444
  • Jaimes Sánchez, Alex
  • Gómez García, Andrea
  • Morollón Sánchez-Mateos, Noemí|||0000-0003-4256-4210
  • Belvís, Roberto|||0000-0002-2137-180X
  • Navarro Pérez, María Pilar|||0000-0001-6370-218X
  • García-Moncó, Juan Carlos
  • Álvarez Escudero, María Rocío
  • Montes, Nuria
  • Gago-Veiga, Ana Beatriz|||0000-0002-0038-3406
Background and purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAb) may be considered after 12-18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption. Methods: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti-CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti-CGRP MAb (T-baseline); last month of first treatment period (T-suspension); month of restart due to worsening (T-worsening); and 3 months after resumption (T-reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD. Results: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T-baseline was 20 (13) and MMD was 5 (6); at T-suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T-worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T-reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001). Conclusion: The results suggest that anti-CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Angiogenic factors and fetal Doppler for predicting adverse pregnancy outcome in early-onset small fetuses with and without pre-eclampsia

  • Casellas de Miguel, Alba
  • Dalmau Artal, Marta
  • Díaz Fernández, Patricia
  • Temprado Piqueras, Joaquin
  • Duaso, M.
  • Ampurdanés Noró, Queralt
  • Armengol, T.
  • Lizarraga, Z.
  • Bonacina, Erika
  • Armengol Alsina, Mireia
  • Roldán Alarcón, Eva
  • San José Moya, Marta
  • Maiz, Nerea
  • Mendoza, Manel
Doppler; Angiogenic factors; Fetal growth restriction, Doppler; Factores angiogénicos; Restricción del crecimiento fetal, Doppler; Factors angiogènics; Restricció del creixement fetal, Objectives To assess the predictive performance of angiogenic factors and fetal Doppler, alone and in combination, for composite adverse perinatal outcome (CAPO) in early-onset small-for-gestational age (SGA) and fetal growth restriction (FGR), in cases both with and without pre-eclampsia (PE), in order to evaluate the ability of these markers to predict adverse outcomes beyond their established association with PE and to better delineate the specific contribution of PE to their predictive value. Methods This was a retrospective observational study conducted at Vall d'Hebron University Hospital, Barcelona, Spain, between January 2016 and January 2022. The study population included singleton pregnancies with an estimated fetal weight < 10th percentile, diagnosed with fetal smallness between 20 + 0 and 31 + 6 weeks' gestation, with fetal Doppler ultrasound data and available angiogenic factor measurements obtained at diagnosis. Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) were measured at initial assessment. CAPO was defined as the presence of at least one of the following: 5-min Apgar score < 7; umbilical cord arterial pH < 7.0; admission to the neonatal intensive care unit for > 48 h; stillbirth; neonatal death; respiratory distress syndrome; bronchopulmonary dysplasia; neonatal sepsis; necrotizing enterocolitis; Grade-III–IV retinopathy of prematurity; Grade-III–IV intraventricular hemorrhage; or periventricular leukomalacia. Predictive performance for CAPO and subsequent PE was assessed using receiver-operating-characteristics (ROC)-curve analysis and area under the ROC curve (AUC) comparisons for fetal Doppler and angiogenic factors, alone and combined, within logistic regression models. Sensitivity, false-positive rate, positive predictive value and negative predictive value were calculated. All analyses were stratified according to PE development at any time before delivery. Results Overall, 469 women with an early-onset small fetus were included. PE was present at diagnosis in 74/469 (15.8%) cases and developed later in 83 (17.7%) cases. CAPO occurred in 46.5% of cases. In the overall cohort, PlGF combined with fetal Doppler findings showed the highest predictive performance for CAPO (AUC, 0.866 (95% CI, 0.833–0.899)), outperforming fetal Doppler alone. Notably, the performance of the combined model was not significantly different from PlGF alone (AUC, 0.862 (95% CI, 0.828–0.895); P = 0.621). These findings were consistent in pregnancies without PE, in which PlGF remained the best-performing single predictor of CAPO (AUC, 0.797 (95% CI, 0.740–0.854)). In pregnancies with PE at any time, the best-performing single predictor was the sFlt-1/PlGF ratio (AUC, 0.802 (95% CI, 0.728–0.876)). For the prediction of subsequent PE after enrolment, the sFlt-1/PlGF ratio alone (AUC, 0.861 (95% CI, 0.821–0.901)) and in combination with fetal Doppler (AUC, 0.862 (95% CI, 0.822–0.902)) achieved the highest predictive performance. Combining fetal Doppler findings with angiogenic factors reduced false-positive rates, but did not improve sensitivity. Conclusion This study confirmed the robust predictive performance of PlGF and the sFlt-1/PlGF ratio for identifying CAPO and PE in early-onset SGA/FGR. The predictive value of PlGF and fetal Doppler remained consistent irrespective of PE status, while the sFlt-1/PlGF ratio showed reduced predictive accuracy in non-PE pregnancies, but still outperformed Doppler. These findings support the integration of angiogenic factors into the clinical assessment of early-onset SGA/FGR, for both cases with and those without PE. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., E.B. has been funded by Instituto de Salud Carlos III (ISCIII) through the project ‘JR23/00004’ and cofunded by the European Union. M.A.-A. has been funded by ISCIII through the project ‘CM23/00017’ and cofunded by the European Union. M.M. and E.B. received lecture fees from Roche Diagnostics.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Early treatment in migraine – A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society

  • Özge, Aynur
  • Pozo-Rosich, Patricia
  • Caronna, Edoardo
  • Sacco, Simona
  • Peres, Mario F P
  • Ashina, Sait
Anti-CGRP therapies; Migraine preventive treatment; Preventive treatment, Terapias anti-CGRP; Tratamiento preventivo de la migraña; Tratamiento preventivo, Teràpies anti-CGRP; Tractament preventiu de la migranya; Tractament preventiu, Migraine is one of the most disabling diseases worldwide, especially when it transforms into chronic migraine, which is often associated with medication overuse and can become resistant or even refractory to treatments. Molecular, neuroimaging and neurophysiological changes have been described in chronic migraine, some of which might not be fully reversible with preventive treatment. For these reasons, we should aim to prevent this transition, and initiate preventive treatment before disease becomes refractory and burden increases. Preventive migraine treatments are often delayed because of access to care, stigma leading to undertreatment and patients' reluctance as a result of fear of side effects and, in some cases, fear of being labeled as chronically ill. With the availability of effective and well-tolerated preventive treatments, we must shift our mindset and take advantage of new opportunities to initiate preventive treatment earlier. In this International Headache Society position statement, we propose a migraine preventive strategy under the idea of shifting from reactive treatment once disability is established (prevention of attacks), to proactive, individualized prevention initiated early with safe, effective and tolerable therapies (prevention of disease progression). This approach is based on 1) promoting the early initiation of effective and tolerable preventive therapies, starting from two to four monthly migraine days in line with the majority of current guidelines and recommendations and 2) fostering longitudinal studies to gather more evidence on the potential benefit of early prevention, with the final goal of improving patient outcomes, promoting excellent migraine care, enhancing individual and social well-being, and, ultimately, preventing migraine progression and preserving brain health., EC has received honoraria from Novartis, Chiesi, Lundbeck, MedScape, Lilly, TEVA, Organon and Dr Reddy's; his salary has been partially funded by Río Hortega grant Acción Estratégica en Salud 2017–2020 from Instituto de Salud Carlos III (CM20/00217) and Juan Rodés fellowship, Subprograma Estatal de Incorporación de la Acción Estratégica en Salud 2023 (JR23/00065). He is a junior editor for Cephalalgia.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Optimizing Chronic Migraine Care: The Impact of Advanced Practice Nurse Involvement in OnabotulinumtoxinA Administration

  • Gine-Cipres, Eulalia
  • Gallardo López, Víctor J.
  • TORRES-FERRUS, MARTA
  • Alpuente Ruiz, Alicia
  • Caronna, Edoardo
  • Gómez Dabó, Laura
  • Pozo-Rosich, Patricia
Advanced practice nursing; Botulinum toxin type A; Headache, Infermeria de pràctica avançada; Toxina botulínica tipus A; Mal de cap, Enfermería de práctica avanzada; Toxina botulínica tipo A; Dolor de cabeza, Background: Chronic migraine is a disabling and prevalent neurological disease that significantly impacts patients' quality of life. OnabotulinumtoxinA (OnabotA) is a safe and effective chronic migraine preventive treatment. The objective was to evaluate adherence to the recommended time interval between consecutive OnabotA injections according to the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) protocol, and to analyze changes in the interval adherence before and after the introduction of an Advanced Practice Nurse (APN) in a specialized Headache Unit of a tertiary hospital. Methods: This was a retrospective study performed in a Spanish specialized Headache Clinic. Patients diagnosed with chronic migraine and treated with OnabotA following the PREEMPT protocol were included, before and after the introduction of APNs. Treatment was considered interval-compliant if the injection interval ranged from 75 to 105 days. The data collected included three 18-month periods. Statistical analyses examined differences across periods using R-Studio. Results: A total of 2991 participants were included, of whom 83.8% (2507/2991) were women, with a median age [interquartile range (IQR)] of 48.0 [40.0–57.0] years old. A statistically significant association between the introduction of the APN and improved adherence to the PREEMPT protocol was observed over time (Z = –19.60, p < 0.001). Adherence rates increased from 52.1% in P1 to 76.1% in both P2 and P3. The median time between visits decreased from 105 days in P1 to 96 days in P2, with a slight increase to 98 days in P3. Conclusion: The involvement of advanced practice nurses in OnabotA administration decreased the time interval between infiltrations and improved adherence to the PREEMPT protocol. These findings highlight the APN's role in optimizing patient care.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Neck pain in migraine: A narrative review and steps to correct evaluation and treatment

  • Rees, Tayla
  • Doukhi, Diana
  • Wang, Victor S
  • Balcerbula, Anita
  • Bravo, Michelle
  • fathi, haniyeh
  • Caronna, Edoardo
  • Pozo-Rosich, Patricia
Evaluation; Migraine; Neck pain, Avaluació; Migranya; Dolor cervical, Evaluación; Migraña; Dolor cervical, Background Neck pain is common in migraine patients, occurring during all migraine phases and between attacks. It can be a migraine symptom, trigger or a coexisting condition, and is associated with greater disability and poorer treatment response. There is evidence that neck pain associated with headaches can be frequently incorrectly diagnosed as a cervical disorder rather than migraine, resulting in a lack of appropriate treatment. Accurately assessing the connection between neck pain and migraine is crucial for effective treatment. Methods This narrative review aims to summarise existing research on the role and contribution of neck pain in migraine, both as a symptom and a trigger, and outlines future research needed to deepen our understanding of this relationship. It also proposes a structured approach for assessing neck pain in migraine and a treatment algorithm, offering guidance for clinical evaluation and treatment. For this purpose, a comprehensive narrative review was conducted using PubMed, covering preclinical, clinical, neurophysiological and imaging evidence on migraine and neck pain. Results Migraine patients frequently exhibit cervical dysfunction, tenderness and altered posture, with overlapping neuroanatomical pathways of the neck and trigeminal systems, suggesting shared mechanisms of nociception and migraine initiation. Clinical assessment involves a thorough history, physical exam and exclusion of secondary causes. Standard migraine therapies, such as amitriptyline and onabotulinumtoxinA, may help reduce neck pain and non-pharmacological treatments, such as physical therapy, acupuncture and behavioural strategies, show some promise. However, evidence on neck pain relief is limited. Conclusions Accurately distinguishing whether neck pain is a symptom, trigger or comorbid condition in migraine is essential for guiding effective treatment strategies. Both pharmacological and non-pharmacological approaches may help manage migraine-associated neck pain. However, few studies have assessed the effects of acute or preventive migraine therapies, particularly calcitonin gene-related peptide-targeted treatments, on neck pain, highlighting a significant gap in our current knowledge. Future research should evaluate the effectiveness of these therapies on neck pain, both alone and in combination with non-pharmacological interventions., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: TAR acknowledges receipt of the International Headache Society Fellowship from the International Headache Society. EC’s salary has been partially funded by Río Hortega grant Acción Estratégica en Salud 2017–2020 from Instituto de Salud Carlos III (CM20/00217) and Juan Rodés fellowship, Subprograma Estatal de Incorporación de la Acción Estratégica en Salud 2023 (JR23/00065).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Cost–benefit analysis of first-trimester pre-eclampsia screening: comparison of multivariable Gaussian algorithm with and without placental growth factor, Análisis de costo-beneficio de la detección de la preeclampsia en el primer trimestre: comparación del algoritmo multivariable de Gauss con y sin factor de crecimiento placentario

  • Armengol Alsina, Mireia
  • Dalmau Artal, Marta
  • Casellas de Miguel, Alba
  • Roldán Alarcón, Eva
  • Kumari , Neeti
  • Arias García, Andrea
  • Bonacina, Erika
  • del Barco Martínez, Ester
  • Ferrer Costa, Roser
  • Maiz, Nerea
  • Mendoza, Manel
First trimester; Pre‐eclampsia; Screening, Primer trimestre; Preeclampsia; Cribado, Primer trimestre; Preeclàmpsia; Cribratge, Objective Pre-eclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Early identification of high-risk pregnancies in the first trimester allows preventive treatment with low-dose aspirin. This study aimed to evaluate whether multivariable Gaussian algorithm-based PE screening strategies, with and without placental growth factor (PlGF), are cost beneficial compared with no screening. Methods The cost–benefit analysis estimated the total healthcare savings for the two screening strategies compared with no screening, considering both the costs associated with implementing the screening and the savings derived from the number of cases of PE and preterm infants prevented. The analysis was based on real-world data from Catalan maternity centers applied to a cohort of 56 344 pregnancies (annual birth rate in 2023). Univariable sensitivity and best- and worst-case scenario analyses were also conducted. Results Both screening strategies resulted in cost savings compared with no screening. The Gaussian algorithm without PlGF yielded greater healthcare savings (€3.38 million) than did the Gaussian algorithm with PlGF (€3.29 million). However, the addition of PlGF provided greater clinical benefit, preventing a higher number of PE cases. Sensitivity analysis identified PE incidence and preterm birth rates as the primary cost drivers. For the PlGF strategy to be cost beneficial, the PlGF reagent cost per unit should not exceed €4.31. Conclusions Although the Gaussian algorithm without PlGF demonstrated the highest cost savings compared with no screening, incorporating PlGF further improved PE prevention, supporting its broader adoption. A PlGF reagent cost per unit below €4.31 may make this strategy cost-beneficial, enhancing its clinical implementation. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., Objetivo La preeclampsia (PE) es una de las principales causas de morbilidad y mortalidad materna y neonatal en todo el mundo. La identificación precoz de los embarazos de alto riesgo en el primer trimestre permite el tratamiento preventivo con dosis bajas de aspirina. El objetivo de este estudio fue evaluar si las estrategias de detección de la PE basadas en algoritmos multivariables de Gauss, con y sin factor de crecimiento placentario (FCPl), son rentables en comparación con la ausencia de pruebas de detección. Métodos El análisis de costo-beneficio estimó el ahorro sanitario total de las dos estrategias de detección en comparación con la ausencia de pruebas de detección, para lo cuál se consideraron tanto los costos asociados a las pruebas de detección como el ahorro derivado de la prevención del número de casos de PE y de recién nacidos prematuros. El análisis se basó en datos reales de centros de maternidad catalanes aplicados a una cohorte de 56 344 embarazos (tasa de natalidad anual en 2023). También se realizaron análisis de sensibilidad univariable y análisis de escenarios de mejor y peor caso. Resultados Ambas estrategias de detección supusieron un ahorro de costos en comparación con la ausencia de pruebas de detección. El algoritmo de Gauss sin FCPl produjo un mayor ahorro sanitario (3,38 millones de euros) que el algoritmo de Gauss con FCPl (3,29 millones de euros). Sin embargo, la adición del FCPl proporcionó un mayor beneficio clínico, ya que evitó un mayor número de casos de PE. El análisis de sensibilidad identificó la frecuencia de PE y las tasas de nacimientos prematuros como los principales generadores de costos. Para que la estrategia con FCPl sea rentable, el costo por unidad del reactivo FCPl no debe superar los 4,31 euros. Conclusiones Aunque el algoritmo de Gauss sin FCPl demostró un mayor ahorro de costos en comparación con la ausencia de pruebas de detección, la incorporación del FCPl mejoró aún más la prevención de la PE, lo que apoya su adopción más amplia. Un coste unitario del reactivo FCPl inferior a 4,31 euros puede hacer que esta estrategia sea rentable, lo que favorecería su aplicación clínica., We thank all physicians and participants who agreed to take part in the original studies, and Roche Diagnostics for providing the reagents. We also thank Ciro Salvi for preparing the figures for this paper. E.B. was funded by Instituto de Salud Carlos III (ISCIII) through the project “JR23/00004” and co-funded by the European Union. M.A-A. was funded by Instituto de Salud Carlos III (ISCIII) through the project “CM23/00017” and co-funded by the European Union. M.M. and E.B. received lecture fees from Roche Diagnostics.